Felicitas La Rosee

Dresden, SN 01307, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

HLH: diagnostics revisited and improved.

HLH: diagnostics revisited and improved.

Journal: Blood

Published: November 28, 2024

The development of tissue handling skills is sufficient and comparable after training in virtual reality or on a surgical robotic system: a prospective randomized trial.

The development of tissue handling skills is sufficient and comparable after training in virtual reality or on a surgical robotic system: a prospective randomized trial.

Journal: Surgical endoscopy

Published: December 06, 2023

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

Journal: Leukemia

Published: May 29, 2023

The impact of specific cytokine directed treatment on severe COVID-19.

The impact of specific cytokine directed treatment on severe COVID-19.

Journal: Leukemia

Published: July 22, 2021

Erratum to: Interdisciplinary COVID board for patients with triggered hyperferritinemic Inflammation

Erratum to: Interdisciplinary COVID board for patients with triggered hyperferritinemic Inflammation

Journal: Medizinische Klinik, Intensivmedizin und Notfallmedizin

Published: December 08, 2020

Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.

Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.

Journal: Acta haematologica

Published: August 06, 2020

Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation

Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation

Journal: Medizinische Klinik, Intensivmedizin und Notfallmedizin

Published: July 30, 2020

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

Journal: Leukemia

Published: May 08, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026